Anti-C5a-R antibody [EPR23278-117],Abcam,AB252435
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IHC-P, Flow Cyt, ICC/IF
Platform ID
BAB110968532
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a (PubMed : 10636859, PubMed : 15153520, PubMed : 1847994, PubMed : 29300009, PubMed : 7622471, PubMed : 8182049, PubMed : 9553099). The ligand interacts with at least two sites on the receptor : a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events (PubMed : 7622471, PubMed : 8182049, PubMed : 9553099). Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production (PubMed : 10636859, PubMed : 15153520). See full target information C5AR1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.